# PELOPS (NCT02764541)

> Palbociclib and Endocrine Therapy for LObular Breast Cancer Preoperative Study (PELOPS)

No report yet. It can be ordered.

- Drugs tested: palbociclib
- Indication: early invasive lobular or ductal breast cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02764541
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Dana-Farber Cancer Institute
- Conditions: Breast Cancer
- Interventions: Letrozole; Tamoxifen; Palbociclib; Endocrine Therapy
- Enrollment: 195
- Primary outcome: Difference in Anti-proliferative Activity of Patients Given Letrozole Versus Tamoxifen During the Window Phase
- Primary outcome: Pathologic Complete Response (pCR) of Patients Given Endocrine Therapy Plus Palbociclib and of Endocrine Therapy Alone During the Treatment Phase

## Indexed commentary on PELOPS so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 2
- Podcasts: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=pelops-nct02764541